Strategic investment · Biotech
AdipoSeeds secures investment from Toho Holdings and Kohjin Bio
The financing will support platelet-based drug development and plasma-processing services.
AdipoSeeds announced an equity investment from Toho Holdings and Kohjin Bio on October 16. The Tokyo biotechnology company did not disclose the amount.
The funding supports preparations for a Japanese clinical trial of ADS-01, its experimental treatment for hard-to-heal skin ulcers. The company is also expanding platelet-rich plasma processing with Kohjin Bio and exploring distribution arrangements with Toho Holdings for future regenerative medicine products.
Use of funds
ADS-01 clinical development
Platelet product development
Funding history
Strategic investment · This roundUndisclosed